Impacts of the Zero-Markup Drug Policy on Hospitalization Expenses of Patients with Stroke in Western China: An Interrupted Time Series Analysis
Yanghaotian Wu,Xuemei Han,Jingfu Qiu
DOI: https://doi.org/10.2147/rmhp.s456977
2024-04-04
Risk Management and Healthcare Policy
Abstract:Yanghaotian Wu, 1– 3 Xuemei Han, 3 Jingfu Qiu 1 1 Department of Social Medicine and Health Service Management, School of Public Health, Chongqing Medical University, Chongqing, People's Republic of China; 2 Department of Social Medicine, School of Public Health, Southwest Medical University, Luzhou, People's Republic of China; 3 Institute of Social Medicine and Health Management, School of Public Health, Lanzhou University, Lanzhou, People's Republic of China Correspondence: Jingfu Qiu, School of Public Health, Chongqing Medical University, Yixueyuan Road, Yuzhong District, Chongqing, 400016, People's Republic of China, Email Background: In 2016, an innovative medical pricing reform called zero-markup drug policy (ZMDP) was implemented in selected pilot cities in China, which focuses on curbing the unreasonable growth of medical expenses. This study aimed to evaluate the impacts of ZMDP on medical expenditure of stroke in western China. Methods: The quantitative data of inpatients diagnosed with stroke was extracted from the medical insurance system in 7 tertiary public hospitals. An interrupted time series (ITS) was used to analyze the instantaneous level and long-term trend changes of hospitalization expenses per visit from January 2015 to November 2018. Results: A total of 22,407 stroke inpatients were extracted. The total hospitalization expense per visit had the highest proportion of 20,000 CNY and above (33.66%). After the ZMDP, the median total hospitalization expense and western medicine expense per visit decreased by 631.74 CNY and 966.35 CNY, respectively ( P < 0.001). Before the policy, the total hospitalization expense, traditional Chinese medicine (TCM) expense, examination expense, treatment expense, laboratory expense and surgical expense per visit showed upward trends ( P < 0.05), while the anesthesia expense per visit showed a downward trend ( P < 0.001). When the policy was implemented, the anesthesia expense per visit instantaneously increased by 91.70% ( P < 0.001). After the policy, the total hospitalization expense, western medicine expense, TCM expense, treatment expense and surgical expense per visit changed from upward trends to downward trends ( P < 0.05). The anesthesia expense per visit changed from a downward trend to an upward trend ( P < 0.001), and the examination expense per visit maintained an upward trend ( P =0.005). Conclusion: The economic burden of stroke inpatients decreased significantly with the implementation of the ZMDP, especially for the drug expenses. The medical service expenses increased significantly, reflecting the improvement in the value of medical staff's technical labor. However, the unexpected increase in the examination expenses was likely to be associated with the unreasonable medical compensation mechanism. Keywords: zero-markup drug policy, stroke, interrupted time series, hospitalization expenses, drug expenses Public hospitals are the main component of China's healthcare system, occupying an absolutely dominant position in the healthcare services market. The Chinese government introduced the drug markup policy during a historical period of low socio-economic level and limited government financial resources, allowing public hospitals to sell drugs with a 15% markup on the purchase price, with the aim of maintaining the basic operation of public hospitals and promoting their own development. 1 The policy has played a positive role in improving the operation of public hospitals in the course of their development. However, with the transformation of China's economic system after the reform and opening up, the drug markup gradually evolved into a profit-seeking behavior, and the income from the drug markup became an important part of the income of public hospitals. 2 In the two decades before the policy, China's pharmaceutical expenditures accounted for 45.7% of the total expenditures on health care. 3 Meanwhile, it is also worth noting that the medical staffs' incomes are linked to drug profits, and problems such as abuse of high-priced drugs and over-prescribing are becoming more frequent. 4 Health services have the special nature of being supply-led and demand-led, and health insurance funds are used irrationally, leading to a rapid increase in patients' medical expenses. At the same time, doctors, stimulated by the profit-seeking mechanism, generate provider-induced demand and prescribe large quantities of unnecessary antibiotics, injections and hormone drugs for patients, which has become a major public health problem in China at this stage. 5–7 In view of this, in 2009, China initiate -Abstract Truncated-
health care sciences & services,health policy & services